Clinical Trials Logo

Clinical Trial Summary

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL.


Clinical Trial Description

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%, and the prognosis of children with intermediate and high risk is even worse, so there is an urgent need to explore new and effective treatment methods. A number of in vitro studies have shown that arsenic trioxide (ATO), which is safe and effective in the treatment of APL, can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. The UK ALL R3 protocol is an advanced and mature clinical trial. The results showed that the MRD negative rate after induction chemotherapy and the 2-year DFS of traditional chemotherapy ±HSCT in children with intermediate and high risk did not reach 50%. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05682131
Study type Interventional
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Pei J Fang, Doctoral
Phone 13682290830
Email jpfang2005@163.com
Status Recruiting
Phase Phase 4
Start date September 27, 2022
Completion date September 27, 2030

See also
  Status Clinical Trial Phase
Completed NCT05621629 - Management of FI After Surgery of ARM
Completed NCT04663516 - Effectiveness of Exercise Through Video Games in Reducing Fatigue Among Children With Leukemia N/A
Recruiting NCT05858593 - Positive Youth Development in the Metaverse N/A
Not yet recruiting NCT04640064 - Hb A1C Pre and Post Confinement in Latin American Children With Type 1 Diabetes: Dulce Study Group
Active, not recruiting NCT01733953 - Statin Therapy in Young Adult Survivors of Childhood Cancer Phase 2
Recruiting NCT04794296 - Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Completed NCT05059756 - PTNS and PFR in the Treatment of Childhood Constipation N/A
Completed NCT06179732 - Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities Phase 3
Recruiting NCT05303155 - The Association of Gut Microbiota With COVID 19 Infection in Children
Completed NCT04800848 - Effects of the Face Mask on Physical Fitness in Children
Not yet recruiting NCT04120896 - Karate or Kung Fu? N/A